Speed to Market Can Destroy Long-Term Value.

Speed to Market Can Destroy Long-Term Value.

One Idea Worth Acting On.

A company rushes its oncology therapy into a narrow, late-line indication.

The development team celebrates the early regulatory win.

The celebration is a trap.

The moment that drug launched, a countdown clock started — one that will erode the asset's commercial and clinical value before it ever reaches the broader patient population it was designed for.

The issue is not speed. It is timing.

What's Actually Happening

The industry has operated for decades on a simple assumption: get to market first, expand the label later. Narrow the trial, accelerate the timeline, secure the approval, then build from there.

That model is now breaking down.

Under the Inflation Reduction Act, the exclusivity countdown begins the moment a drug launches — in any indication. A company that launches two years early in a small third-line indication does not gain two years. It loses two years from the asset's peak commercial window.

As Daniel Switzer, Head of the US Oncology Business Division at Daiichi Sankyo and contributor to Voices of Oncology, states directly: if a company launches a small indication two years before the primary indication is ready, it permanently loses two years of the product's life.

Permanently. Not delayed. Gone.

Why This Matters

The commercial runway for an oncology asset is not infinite. When the exclusivity clock starts early on a narrow indication, everything downstream compresses — the peak revenue period, the investment available for further development, the economic case for pursuing additional indications in smaller or rarer patient populations.

The patients who suffer most are often those with less common disease states. When the economics of a program weaken because the exclusivity window was burned on a narrow early launch, the incentive to continue developing for those populations weakens with it.

A fast approval that shrinks the lifecycle of an asset is not a competitive advantage. It is a strategic miscalculation dressed as momentum.

Where It Breaks in the Real World

The breakdown is structural. Clinical Development is incentivized to secure the fastest possible regulatory win. Commercial, Market Access, and HEOR are brought in after the indication strategy is already set.

By the time those functions flag the lifecycle implications of the narrow launch, the trial is enrolled, the filing is submitted, and the decision is irreversible.

Kasem Akhras, OVN's Market Access contributor, describes the consequence precisely: a drug approved in a small indication where three competitors already hold reimbursement may not receive reimbursement at all — because the payer sees no incremental value. The fast approval produced a fast rejection at the payer level, and the asset's path to the broader indication is now running against a shorter exclusivity clock.

What Needs to Change

Indication sequencing is a lifecycle strategy decision — not a clinical operations decision made in isolation. Commercial, Market Access, and HEOR belong in the indication sequencing conversation before the Target Product Profile is endorsed, not after the Phase 3 protocol is filed.

Sometimes the right strategic move is to wait. To take the time to generate the data that will define the drug's best indication — the one where the clinical benefit is most compelling, the payer evidence is strongest, and the exclusivity window will be used at its highest commercial value.

Speed is a weapon. It has to be pointed in the right direction.

The Bottom Line

Rushing to market is no longer a default advantage. In today's policy environment, an early launch in the wrong indication can permanently diminish the value of a drug that should have been transformative.

The discipline to sequence strategically — to move smart rather than just fast — is one of the most valuable capabilities in oncology development right now. And one of the rarest.

Add Your Voice — Where are you seeing this? What's working — and what's not?